Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions.
Specific transaction details include:
- Share Price: 1,546.50 pence per Ordinary Share and $50.22 per American Depositary Share (ADS).
- Transaction Type: Increases in notional interests following the re-investment of dividends paid on October 3, 2013.
- Participants: Includes Sir Andrew Witty, Mr. S. Dingemans, Dr. M. M. Slaoui, and other senior executives.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It reports routine administrative updates regarding the accrual of notional dividends within the deferred bonus plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share plan activities.
Investor Verification Checklist
- Verify the total number of shares and ADSs acquired by each named executive under both personal and company contribution elements.
- Confirm the vesting schedule and measurement period for the deferred annual bonus holdings mentioned.
- Review the dividend reinvestment price of 1,546.50 pence per Ordinary Share against market prices on October 3, 2013.
- Check subsequent filings for the actual payout of notional dividends upon vesting.